2023
Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients
Makinde H, Dunn JLM, Gadhvi G, Carns M, Aren K, Chung AH, Muhammad LN, Song J, Cuda CM, Dominguez S, Pandolfino JE, D'Amico J, Budinger GS, Assassi S, Frech TM, Khanna D, Shaeffer A, Perlman H, Hinchcliff M, Winter DR. Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients. Arthritis & Rheumatology 2023, 75: 595-608. PMID: 36281773, PMCID: PMC10165944, DOI: 10.1002/art.42380.Peer-Reviewed Original ResearchConceptsDiffuse cutaneous systemic sclerosisNonclassical monocytesClassical monocytesSSc patientsTranscriptional signatureSystemic sclerosisSkin diseasesCharacteristic transcriptional signaturesRNA-seq dataSSc skin diseaseWorse lung functionCutaneous systemic sclerosisEarly systemic sclerosisActivity outcome measuresDistinct transcriptional profilesTranscriptional profilingRNA sequencingTranscriptional profilesProspective registryDisease activityLung functionComplex clinical phenotypeGene expressionPeripheral bloodMinority cell population
2016
The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis
Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology 2016, 55: 911-917. PMID: 26880832, PMCID: PMC5854039, DOI: 10.1093/rheumatology/kew003.Peer-Reviewed Original ResearchConceptsRodnan skin scoreHealth Assessment QuestionnaireSkin symptomsSkindex-29Skin scoreAssessment QuestionnaireSkin diseasesSkin pathologySSc skin diseaseSymptom assessment questionnairePatient's skin symptomsSSc patientsSystemic sclerosisAtopic dermatitisPathological featuresSymptom assessmentPhysical examMyofibroblast infiltrationPathological changesPathological measuresPatientsSymptom instrumentsSymptomsDiseaseSHAQ
2013
Treatment of early diffuse systemic sclerosis skin disease.
Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT. Treatment of early diffuse systemic sclerosis skin disease. Clinical And Experimental Rheumatology 2013, 31: 166-71. PMID: 23910619, PMCID: PMC3889109.Peer-Reviewed Original ResearchConceptsSSc skin diseaseSystemic sclerosisSkin diseasesEarly diffuse cutaneous systemic sclerosisDiffuse cutaneous systemic sclerosisEarly diffuse SScEarly systemic sclerosisCutaneous systemic sclerosisDiffuse systemic sclerosisIncident cohort studyIntravenous immunoglobulinProspective registryCohort studyInter-institutional variabilityClinical courseHigh morbidityDiffuse SScEffective treatmentNovel biomarkersDisease pathogenesisSclerosisDiseaseTreatmentRigorous studiesMycophenolate